Since its grand opening on April 28, 2007, Richland International Hospital (RIH) has developed an excellent healthcare management system for all departments and follows the standards of the Joint Commission International (JCI). It is also the first hospital to operate with a full information technology system in the South-West part of China and is already serving about 7,900 local high net-worth patients and about 680 foreign patients since its grand opening. The Government of Yunnan Province has paid close attention to RIH achievements and has granted the following:

1. Three years tax-free exemption benefit and has announced RIH as one of the major Joint Venture Hospitals in Kunming City.

2. RIH is the first and the only hospital permitted to recruit foreign medical staff including physicians and nurses in the Yunnan Province.

3. RIH is first and the only hospital permitted to legally serve foreign patients in the Yunnan Province.

4. RIH has been designated as one of the Province's approved insurance coverage hospitals.

"Our marketing plan for 2008 is to establish a brand name for Richland International by focusing on the high-level healthcare services market and aim to expand our memberships rapidly starting from the City of Kunming and extending thru to the greater Yunnan Province. The market has already been proven that there is a tremendous demand for high-level healthcare and medical services," says Dr. Xu Mei, CEO of China Health Management Services and Chairman of Richland International Hospital.

About China Health Management Corp.

China Health Management Corp. is a healthcare management company focused on Operations and Management of hospitals in China. The company's first target is to become the leader in the high-end healthcare and medical services industry in Kunming city, Yunnan Province, China.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained herein which are not historical are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond the company's control with respect to market acceptance of new technologies or products, delays in testing and evaluation of products, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission.